Piperidine-piperazine ligands for neurotransmitter receptors

Details Piperidine-piperazine ligands for neurotransmitter receptors Piperidine-piperazine ligands for neurotransmitter receptors

2005-08-30

2005-08-30

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253130, C544S360000

Reexamination Certificate

active

06936614

ABSTRACT:
One aspect of the present invention relates to piperidine-piperazine compounds. A second aspect of the present invention relates to the use of the piperidine-piperazine compounds as ligands for various mammalian cellular receptors or transporters or both, including dopamine, serotonin or norepinephrine receptors or transporters, any combination of them, or all of them. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the piperidine-piperazine compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine receptors or transporters or both.

REFERENCES:
patent: 4873331 (1989-10-01), Childers, Jr. et al.
patent: 5643927 (1997-07-01), Foguet et al.
patent: 5665725 (1997-09-01), Moltzen et al.
patent: 5807871 (1998-09-01), Moltzen et al.
patent: 5859246 (1999-01-01), Thurkauf et al.
patent: 5965575 (1999-10-01), Peglion et al.
patent: 6031099 (2000-02-01), Moltzen et al.
patent: 6084098 (2000-07-01), Kover et al.
patent: 6172229 (2001-01-01), Thurkauf et al.
patent: 6207677 (2001-03-01), Moltzen et al.
patent: 6239126 (2001-05-01), Kelly et al.
patent: 6239135 (2001-05-01), Kohlman et al.
patent: 6251893 (2001-06-01), Maddaford et al.
patent: 6255302 (2001-07-01), Kelly et al.
patent: 6284759 (2001-09-01), He
patent: 6316470 (2001-11-01), Kover et al.
patent: 6333339 (2001-12-01), Boerttcher et al.
patent: 6358958 (2002-03-01), Kohlman et al.
patent: 6376494 (2002-04-01), Childers et al.
patent: 6713479 (2004-03-01), Persons et al.
patent: WO 95/25733 (1995-09-01), None
patent: WO 98/57953 (1998-12-01), None
patent: WO 99/65906 (1999-12-01), None
International Search Report Completed on Jun. 29, 2002 and Mailed on Aug. 8, 2002.
Basic & Clinical Pharmacology, (6th. Ed.) by Appleton & Lange, pp. 132-141 (1995).
Van Tol, et al., “Cloning Of The Gene For A Human Dopamine D4 Receptor With High Affinity For The Antipsychotic Clozapine”, Nature, vol. 350, pp. 610-614 (1991).
Robichaud, A.J., et al., “Recent Advances in Selective Serotonin Receptor Modulation”, Annual Reports in Medicinal Chemistry, vol. 35, pp. 11-20 (2000).

Affiliated with

Also associated with

Rating

Piperidine-piperazine ligands for neurotransmitter receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine-piperazine ligands for neurotransmitter receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine-piperazine ligands for neurotransmitter receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3440558